MEA Continuous Glucose Monitoring Market - Strategic Insights and Forecasts (2026-2031)

The Middle East and Africa Continuous Glucose Monitoring (CGM) market is forecast to grow at a CAGR of 12.8%, reaching USD 122.8 million in 2031 from USD 67.3 million in 2026.

A continuous glucose monitor is a wearable medical device for people with type 1 or type 2 diabetes that continuously monitors their blood glucose levels. Tracking blood sugar levels is extremely essential for diabetic patients, as they have to make sure when to take insulin, and CGM devices help them in determining that. CGM is a widely used technology as it is advantageous for diabetics. Studies have shown that the use of CGM devices ensures a shorter duration of hypoglycemia or a lower level of glycated haemoglobin. The continuous glucose monitoring market in the Middle East and Africa is segmented into application, end-user industry and country.

The growing prevalence of type 1 and type 2 diabetes in countries such as Israel, Saudi Arabia and the UAE, along with rising government initiatives and programmes to educate people about diabetic health & care, are some of the key determinants which are positively impacting the demand for CGM devices in this region.

However, the high price of CGM devices and the lack of reimbursement policies by the medical insurance provider in this region are obstructing the growth of the regional market for continuous glucose monitoring devices during the analysis period.

MEA Continuous Glucose Monitoring Market Drivers:

• During the anticipation period, the growing incidence of diabetes will support the growth of the MEA continuous glucose monitoring market during the projection period.

One of the primary factors driving the growth of continuous glucose monitoring devices in the Middle East and Africa region is the high prevalence of type 1 and type 2 diabetes among the population. According to the statistics presented by the International Diabetes Federation, 73 million people aged between 20 and 79 suffered from diabetes in 2021 in the MEA region. Between 2030 and 2045, this number is projected to rise to 95 million and 136 million, respectively.

In the IDF Middle East and North Africa region, there are 27 million individuals with diabetes who have never received a diagnosis, accounting for 38 per cent of the region's total adult diabetic population. 48 million people have impaired glucose tolerance, which increases their risk of type 2 diabetes. By 2030 and 2045, this number is projected to rise to 36 million and 81 million, respectively. In 2021, diabetes will be the cause of 796,000 fatalities in the IDF MENA Area. The prevalence of diabetes has alarmingly increased across the Middle East and Africa in recent years, reaching an all-time high, mostly due to lifestyle changes. Diabetes patients must make several adjustments throughout the day to keep their blood glucose levels within acceptable ranges. Therefore, CGM devices are extremely crucial for them.

MEA Continuous Glucose Monitoring Market Geographical Outlook:

• Saudi Arabia is anticipated to hold a significant MEA CGM market share during the forecast period.

Saudi Arabia is anticipated to hold a significant market share in continuous glucose monitoring devices. This region will witness high growth during the forecast period owing to the high prevalence of diabetes among the Saudi population. According to a survey by the International Diabetes Federation, more than one in ten Saudi Arabians is suffering from diabetes, and by 2045, that number will practically double. Out of Saudi Arabia's population of 34.8 million, 4.27 million have diabetes, and another 1.86 million have the disease but have not yet been given a diagnosis, according to an IDF study. This number is expected to increase to 5.6 million by 2030 and 7.5 million by 2045.

The rising adoption of new technology is also propelling the market growth. Government initiatives have also facilitated market expansion in this country, and the healthcare sector is also spurring growth for CGM devices. In July 2022, the Saudi government said there was an increase in the need for high-quality healthcare services in Saudi Arabia due to demographic trends, such as ageing and the rising incidence of lifestyle disorders, including diabetes and obesity. To ensure affordability, accessibility, and high-quality primary care with cost-effectiveness, the government is aiming to ensure that all Saudi residents have medical insurance coverage. Moreover, the government of this country plans to invest US$ 66 billion in the healthcare sector by 2030 and boost the private sector.

MEA Continuous Glucose Monitoring Market Developments:

• In October 2022, the sugarBEAT® system by Nemaura Medical, Inc received a provisional purchase order from TPMENA, the company's MENA license. Nemaura Medical, Inc., is a medical technology company focused on developing and commercialising noninvasive wearable diagnostic devices like CGM devices and supporting customised lifestyle coaching programmes. The sugarBEAT® system is a noninvasive AI-driven CGM device.

• In October 2022, Dexcom introduced the Dexcom G7, a next-generation continuous glucose monitor (CGM), for diabetics two years of age and above. The Dexcom G7 improves on the Dexcom CGM by adding new features such as a 60as % smaller, all-in-one, discrete wearable and the quickest 30-minute sensor warm-up of any CGM on the market.

MEA Continuous Glucose Monitoring Market Scope:

MEA Continuous Glucose Monitoring Market Segmentation:

• By Application

  • Diabetes Patients

  • Critical Patients

• By End User

  • Hospitals

  • Diagnostic Centers & Clinics

  • Home Care

• By Country

  • UAE

  • Israel

  • Others